Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198068 · ClinicalTrials.gov registry record
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
A clinical trial of Systemic Lupus Erythematosus and Antiphospholipid Syndrome, sponsored by Hospital for Special Surgery, New York.
- Recruiting
- Registry status
- 700
- Enrollment target
- 10
- Study locations
NCT00198068 is a study of Systemic Lupus Erythematosus and Antiphospholipid Syndrome that is actively recruiting participants, run by Hospital for Special Surgery, New York. The registered enrollment target is 700 participants, above the 373-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (88% higher). The trial reports 10 study locations across 7 states.
The verdict
NCT00198068, a study of Systemic Lupus Erythematosus and Antiphospholipid Syndrome, is actively recruiting participants, sponsored by Hospital for Special Surgery, New York.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 10
- Study locations
Study Summary
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE.
Conditions Studied
Study Locations (10)
New York
- NYU Langone Medical Center/Hospital for Joint Diseases - New York
- Hospital for Special Surgery - New York
- Columbia University Medical Center - New York
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
Maryland
- Johns Hopkins Hospital - Baltimore
Oklahoma
- Oklahoma Medical Research Foundation - Oklahoma City
Utah
- University of Utah Salt Lake City - Salt Lake City
Ontario
- Mt. Sinai Hospital - Toronto
Other
- Guy's & St Thomas' NHS Foundation Trust - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2003-09 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198068
The ClinicalTrials.gov registry entry for NCT00198068 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 373-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (88% higher). The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 0 interventions.
NCT00198068 reports 10 study locations spanning 7 distinct geographic areas - top geographies include New York, Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT00198068 about?
NCT00198068 is a clinical study titled "Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)". The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in pati...
What is the current status of trial NCT00198068?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2003-09. Estimated completion is 2026-03.
What conditions does trial NCT00198068 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome.
Who is sponsoring clinical trial NCT00198068?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00198068 being conducted?
This trial has 10 study locations across Illinois, Maryland, New York, Oklahoma, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
RECRUITING
-
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.